Roche Holding AG (RHHBY)
| Market Cap | 333.72B |
| Revenue (ttm) | 79.83B |
| Net Income (ttm) | 11.86B |
| Shares Out | n/a |
| EPS (ttm) | 14.77 |
| PE Ratio | 28.15 |
| Forward PE | 16.62 |
| Dividend | 0.87 (1.79%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 455,025 |
| Average Volume | 2,131,377 |
| Open | 48.52 |
| Previous Close | 48.04 |
| Day's Range | 48.50 - 49.09 |
| 52-Week Range | 34.10 - 49.20 |
| Beta | 0.17 |
| RSI | 71.77 |
| Earnings Date | Oct 27, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial numbers in CHF Financial StatementsNews
Olema Pharmaceuticals: Shares Double On Roche's MBC Data - I Preach Caution
KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors
PITTSBURGH--(BUSINESS WIRE)--KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapies, today announced a clinical t...
Roche: European Commission Grants Conditional Marketing Authorisation Of Lunsumio
(RTTNews) - Roche (RO.SW) announced that the European Commission has granted conditional marketing authorisation of Lunsumio, or mosunetuzumab, subcutaneous for the treatment of adult patients with re...
European Commission approves Roche's Lunsumio subcutaneous for relapsed or refractory follicular lymphoma
Basel, 19 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted conditional marketing authorisation of Lunsumio® (mosunetuzumab) subcutaneous (SC)...
Market bubbles cracking: Gold & defense stocks the go‑to strategy, says David Roche
David Roche of Quantum Strategy told CNBC’s Squawk Box Asia that bubbles in AI and credit markets are beginning to crack, posing serious economic risks. While he noted the fallout is unlikely to reach...
Why biotech and drug stocks are on the mend even though the rest of the market is hurting
Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded away.
RHHBY Reports Positive Phase III Data on Breast Cancer Drug
Roche reports strong phase III lidERA results as giredestrant delivers meaningful iDFS gains over standard endocrine therapy.
Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock
Shares of Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) soared Tuesday in reaction to Roche Holdings AG ‘s (OTC: RHHBY) phase 3 results from the lidERA Breast Cancer study of giredestrant in early-stag...
Roche's $15 Billion Breast Cancer Pill Just Stunned the Market--But AstraZeneca Is Lurking
Roche's $15 Billion Breast Cancer Pill Just Stunned the Market--But AstraZeneca Is Lurking
Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why
Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a favorable safety profile. Latest Ratings for RHHBY ... Full story available o...
Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200%
Biotech stock Olema Pharmaceuticals catapulted to a four-year high Tuesday after Roche unveiled positive results in breast cancer treatment.
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are rushing to boost U.S. manufacturing and inventory as the Trump administration weighs a 100% tariff on imported branded and patented drugs.
Olema Pharmaceuticals (OLMA) Surges on Roche's Breast Cancer Trial Success
Olema Pharmaceuticals (OLMA) Surges on Roche's Breast Cancer Trial Success
Roche boosts Olema as breast cancer therapy succeeds in late-stage trial
Roche (RHHBY) boosts Olema Pharma (OLMA) stock as its breast cancer drug, giredestrant, similar to Olma's lead drug, succeeds in a Phase 3 trial. Read more here.
Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial
The drugmaker said the results for giredestrant open the door to adding a treatment option at an early stage of the cancer, when most patients are diagnosed.
Roche oral drug shown to keep breast cancer at bay, boosting shares
Roche's ROG.S experimental oral drug giredestrant has been shown to cut the risk of recurrence of a common form of breast cancer after surgery, boosting the company's shares and underpinning its tradi...
Roche: Phase III Study With Giredestrant Meets Primary Endpoint At Pre-planned Interim Analysis
(RTTNews) - Roche (RHHBY) announced positive phase III results from the lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endocrine treatment for people with oestrogen ...
Genentech's Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive Phase III results from the lidERA Breast Cancer study evalua...
[Ad hoc announcement pursuant to Art. 53 LR] Roche's giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer
Basel, 18 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive phase III results from the lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endoc...
Roche’s breast cancer drug Perjeta faces copycats as FDA approves first biosimilar
Roche (RHHBY) stock is in focus as the U.S. FDA approves Poherdy as the first biosimilar targeting the company's breast cancer drug Perjeta. Read more here.
Millennials at highest risk of missing crucial cervical cancer screenings, finds survey commissioned by Roche
New research shows that people aged 29-42 are more likely to miss cervical screenings than any other age group.1 Almost one third of surveyed European millennials eligible for routine cervical screeni...
Why Roche Holding Stock Popped Today
Roche is great at developing drugs -- but is its stock a great buy?
TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results
Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on key rival TG Therapeutics.
Roche (RHHBY) Shares Rise on Positive Phase 3 Trial Results for Fenebrutinib
Roche (RHHBY) Shares Rise on Positive Phase 3 Trial Results for Fenebrutinib